ERAS, Gynecologic Cancer, Nutritional Deficiency
Conditions
Brief summary
A patient with oncological pathology of any type because of impaired digestion and nutrient absorption, decreased intake, and increased nutrition requirements has an increased risk of malnutrition and moderate to severe weight loss.In the present study the investigators will evaluate the impact of perioperative immunonutrition supplementation on the postoperative outcomes.
Detailed description
Malnutrition has a major effect not only on the postoperative course of cancer surgery but can also complicate or even limit administration or compromise the effectiveness of other treatments such as chemotherapy or radiotherapy in the perioperative period. Immunonutrition is a type of artificial nutrition based on the use of some types of macro- or micronutrients.The purpose of this review was to evaluate the use, indications, and effects of these formulas in oncologic surgical patients in real time and to identify the types of patients who can benefit from enteral immunonutrition.
Interventions
DIETARY_SUPPLEMENTImmunonutrition
enteral supplementation with high amount of proteins, arginine, glutamine, nonessential fatty acids, branched chain fatty acids, nucleotides, or RNA
Sponsors
National and Kapodistrian University of Athens
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* women with any gynaecologic malignancy enrolled in surgical list of our institute * must be able to consume oral supplements.
Exclusion criteria
* women that are not able to follow ERAS protocol due to medical reasons * patients with severe disease that cannot compromise with protocol
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Perioperative infections | Postoperatively (30 days) | We will notice possible surgical site infections,respiratory inflammations etc and calculate inflammatory markers and the concentration of white blood cells |
| Duration of hospitalization | Until discharge from hospital | From date of hospitalization until the date of discharge or date of death from any cause, whichever came first, assessed up to 2 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Postoperative mobilization | Until first day of mobilization | From date of surgery until the date of discharge or date of death from any cause, whichever came first, assessed up to 2 months. |
| Postoperative morbidity (other than infectious) | 30 days | Major events such as pulmonary embolism,accuse myocardial infarction,etc |
| Recurrence rates | 3 years follow-up | Recurrent disease will be monitored through 3 year of follow up |
| Overall survival | 3 years follow-up | Overall survival of the patients will be measured through 3 year of follow up |
Countries
Greece
Contacts
Primary ContactNikolaos Thomakos, MD
Outcome results
None listed